Comparative Pharmacology
Head-to-head clinical analysis: NUMBRINO versus TRANEXAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUMBRINO versus TRANEXAMIC ACID.
NUMBRINO vs TRANEXAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); increases synaptic serotonin by inhibiting SERT.
Competitive inhibitor of plasminogen activation, blocking the binding of plasminogen to fibrin, thereby preventing fibrinolysis and stabilizing clots.
2 mg/kg intravenously every 8 hours, max 150 mg per dose.
1 g intravenously every 8 hours for prophylaxis of bleeding in cardiac surgery; for heavy menstrual bleeding: 1.3 g orally three times daily for up to 5 days during menstruation.
None Documented
None Documented
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min)
Clinical Note
moderateTranexamic acid + Estrone sulfate
"Tranexamic acid may increase the thrombogenic activities of Estrone sulfate."
Clinical Note
moderateTranexamic acid + Estramustine
"Tranexamic acid may increase the thrombogenic activities of Estramustine."
Clinical Note
moderateTranexamic acid + Tretinoin
"Tranexamic acid may increase the thrombogenic activities of Tretinoin."
Clinical Note
moderateTranexamic acid + Diethylstilbestrol
Terminal elimination half-life approximately 2-11 hours (mean 2 hours in healthy adults; prolonged to 7-15 hours in renal impairment). Clinical context: dosing interval adjustment required in renal insufficiency.
Renal: 70% unchanged; hepatic metabolism: 20%; fecal: 10%
Primarily renal excretion as unchanged drug (95% within 24 hours) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category A/B
Antifibrinolytic
Antifibrinolytic
"Tranexamic acid may increase the thrombogenic activities of Diethylstilbestrol."